Johnson & Johnson has seen
a healthy 9.9% increase in sales of
prescription drugs during the three
months to 30 Sep.
J&J’s Total prescription drug sales
amounted to US$7 billion, with the
performance led by demand for
items such as Remicade, Velcade,
Stelara, Simponi and Zytiga.The above article was sent to subscribers in Pharmacy Daily's issue from 17 Oct 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Oct 13
PEAK industry bodies have welcomed Labor Government’s 2024-25 Commonwealth Budget handed down last night, which introduced financial relief measures aimed at assisting patients and community pharmacies.
AFFORDABLE healthcare for more Australians was highlighted in yesterday’s Federal Budget, with funds allocated to services for Aboriginal and Torres Strait Islander people.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.